Lyell Immunopharma Presents New Data on Ronde-cel at ASH Meeting
Less than 1 min read
On December 7, 2025, Lyell Immunopharma presented new data on ronde-cel at the ASH Annual Meeting.
Key Highlights:
- Ronde-cel showed a 93% response rate in 3L+ LBCL patients.
- 83% response rate observed in 2L LBCL patients.
- Manageable safety profile with no severe CRS cases.
- Ronde-cel demonstrated robust CAR T-cell expansion.
Original SEC Filing: Lyell Immunopharma, Inc. [ LYEL ] - 8-K - Dec. 08, 2025
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.